<?xml version='1.0' encoding='utf-8'?>
<document id="29199506"><sentence text="Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin."><entity charOffset="23-31" id="DDI-PubMed.29199506.s1.e0" text="imatinib" /><entity charOffset="101-110" id="DDI-PubMed.29199506.s1.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.29199506.s1.e0" e2="DDI-PubMed.29199506.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29199506.s1.e0" e2="DDI-PubMed.29199506.s1.e1" /></sentence><sentence text="Imatinib mesylate and the newer BCR-ABL tyrosine kinase inhibitors are the standard therapy for chronic myeloid leukemia"><entity charOffset="0-17" id="DDI-PubMed.29199506.s2.e0" text="Imatinib mesylate" /><entity charOffset="40-48" id="DDI-PubMed.29199506.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.29199506.s2.e0" e2="DDI-PubMed.29199506.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29199506.s2.e0" e2="DDI-PubMed.29199506.s2.e1" /></sentence><sentence text=" Although these are remarkably effective drugs, some mechanisms of resistance have been identified including drug-to-drug interactions" /><sentence text=" Here we present the case of a chronic myeloid leukemia patient with an inadequate response to imatinib due to concurrent phenytoin administration"><entity charOffset="95-103" id="DDI-PubMed.29199506.s4.e0" text="imatinib" /><entity charOffset="122-131" id="DDI-PubMed.29199506.s4.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.29199506.s4.e0" e2="DDI-PubMed.29199506.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29199506.s4.e0" e2="DDI-PubMed.29199506.s4.e1" /></sentence><sentence text=" Conspicuously low imatinib plasma trough levels were documented"><entity charOffset="19-27" id="DDI-PubMed.29199506.s5.e0" text="imatinib" /></sentence><sentence text=" Imatinib dose was increased from 400 to 800â€‰mg with good response"><entity charOffset="1-9" id="DDI-PubMed.29199506.s6.e0" text="Imatinib" /></sentence><sentence text=" In conclusion, drug-to-drug interactions should be ruled out in cases of resistance to tyrosine kinase inhibitor treatment"><entity charOffset="88-96" id="DDI-PubMed.29199506.s7.e0" text="tyrosine" /></sentence><sentence text=" Potent inducers of cytochrome P450 isoenzyme CYP3A4, as phenytoin, could induce inadequate responses due to increased imatinib clearance and low imatinib trough plasma levels"><entity charOffset="57-66" id="DDI-PubMed.29199506.s8.e0" text="phenytoin" /><entity charOffset="119-127" id="DDI-PubMed.29199506.s8.e1" text="imatinib" /><entity charOffset="146-154" id="DDI-PubMed.29199506.s8.e2" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.29199506.s8.e0" e2="DDI-PubMed.29199506.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29199506.s8.e0" e2="DDI-PubMed.29199506.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29199506.s8.e0" e2="DDI-PubMed.29199506.s8.e2" /><pair ddi="false" e1="DDI-PubMed.29199506.s8.e1" e2="DDI-PubMed.29199506.s8.e1" /><pair ddi="false" e1="DDI-PubMed.29199506.s8.e1" e2="DDI-PubMed.29199506.s8.e2" /></sentence><sentence text=" Thus, this interaction should be avoided" /><sentence text=" When this is not possible, dose escalation of imatinib and measurement of plasma levels, if available, is recommended"><entity charOffset="47-55" id="DDI-PubMed.29199506.s10.e0" text="imatinib" /></sentence><sentence text="" /></document>